- Home
- IOVA vs SNY Comparison
IOVA vs SNY Comparison
Compare IOVA & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- SNY
- Stock Information
- Founded
- IOVA 2007
- SNY 1994
- Country
- IOVA United States
- SNY France
- Employees
- IOVA N/A
- SNY N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- IOVA Health Care
- SNY Health Care
- Exchange
- IOVA Nasdaq
- SNY Nasdaq
- Market Cap
- IOVA 975.1M
- SNY 113.4B
- IPO Year
- IOVA N/A
- SNY N/A
- Fundamental
- Price
- IOVA $2.27
- SNY $47.03
- Analyst Decision
- IOVA Buy
- SNY Buy
- Analyst Count
- IOVA 11
- SNY 4
- Target Price
- IOVA $11.90
- SNY $61.50
- AVG Volume (30 Days)
- IOVA 11.1M
- SNY 2.8M
- Earning Date
- IOVA 11-06-2025
- SNY 10-24-2025
- Dividend Yield
- IOVA N/A
- SNY 3.40%
- EPS Growth
- IOVA N/A
- SNY 118.56
- EPS
- IOVA N/A
- SNY 8.65
- Revenue
- IOVA $241,525,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- IOVA $67.40
- SNY $2.01
- Revenue Next Year
- IOVA $56.32
- SNY $6.82
- P/E Ratio
- IOVA N/A
- SNY $10.74
- Revenue Growth
- IOVA 636.99
- SNY 15.65
- 52 Week Low
- IOVA $1.64
- SNY $44.73
- 52 Week High
- IOVA $12.51
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- IOVA 45.40
- SNY 42.55
- Support Level
- IOVA $2.27
- SNY $46.79
- Resistance Level
- IOVA $2.46
- SNY $47.69
- Average True Range (ATR)
- IOVA 0.15
- SNY 0.71
- MACD
- IOVA -0.00
- SNY -0.27
- Stochastic Oscillator
- IOVA 29.09
- SNY 32.62
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.